None listed
Conditions
Brief summary
Motor neurones are a specific type of neurone that connect our muscles to our central nervous system (brain and spine). Thanks to motor neurones we are able to transform electrical impulses generated in our brain into muscle contractions, translating into strength and movement. Motor neurones have the ability to do this through a phenomenon called persistent inward currents (PIC). Research has shown that in the presence of serotonin, PICs are facilitated, and thus strength is achieved easier. Apparently, caffeine may influence the development of PICs in human motor neurones. Yet, the degree at which caffeine affects PIC and movement is still unknown. Therefore, we are testing the effects of caffeine on PICs, strength development and time to fatigue. We hypothesized that the consumption of caffeine will increase PICs amplitude, increasing levels of force and diminishing fatigue.
Interventions
In this project, we will study the effects of caffeine on parameters of motor function. Participants will be asked to visit the laboratory QUT Kelvin Grove for two sessions (one placebo and one intervention visit) of 3 h each. One week wash-out period will separate each visit. On each visit, participants will be given either a placebo or a single dose of Caffeine (oral capsule with 6 mg/kg of body mass) and neuromuscular assessments will be performed before and 60 min after consuming the capsule
In this project, we will study the effects of caffeine on parameters of motor function. Participants will be asked to visit the laboratory QUT Kelvin Grove for two sessions (one placebo and one intervention visit) of 3 h each. One week wash-out period will separate each visit. On each visit, participants will be given either a placebo or a single dose of Caffeine (oral capsule with 6 mg/kg of body mass) and neuromuscular assessments will be performed before and 60 min after consuming the capsule. All capsules will be prepared by Exercise physiologist with 8 years of research experience. The consumption of capsules will be monitored by the principal investigator.
Sponsors
Karen Mackay
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy non-smokers , BMI <30 kg/m2
Exclusion criteria
Musculoskeletal disorders that limit performance in the assessed limb; diagnosed neurological disorders (e.g. amyotrophic lateral sclerosis or ALS); diagnosed serotonergic disorders (e.g. depression); consumption of drugs that affect serotonin and noradrenaline release (e.g. recreational drugs such as marihuana and ecstasy, SRRIs or antidepressants); Women must not be pregnant, breast feeding or menopausal.
Outcome results
None listed